Alpha Teknova delivered a cleaner-than-expected Q1 and held its full-year sales guidance, yet the short-selling backdrop heading into the May 8 call remains more charged than the headline beat might suggest.
The company posted Q1 revenue of $11.1M, ahead of the $10.2M consensus, and narrowed its per-share loss to $0.08 against an estimate of $0.09. Management affirmed its FY2026 sales range of $42M–$44M, bracketing the $43M analyst estimate almost exactly. The stock had already rallied hard into the numbers — up 13% on the week and 15% on the month — before giving back 2.7% on May 6, suggesting the beat was at least partially priced.
The short-selling picture adds texture. ORTEX's short score reached 73.2 on May 5, near the top of its recent range and placing TKNO in a position where bearish sentiment metrics are clearly elevated despite the stock's recovery from March lows near $2.19. Short interest is running at roughly 2.3% of free float — not extreme in isolation, but the borrow market is noticeably tighter than it was a month ago. Cost to borrow has nearly halved from the 2.4%–2.7% range seen in late March, now at 1.2%, yet it jumped 31% over the past week. Borrow availability sits at around 56% — tighter than it was through much of April, when it briefly reached 100% utilisation at the 52-week peak. That tightening suggests renewed demand for short exposure even as the stock rallied.
The ownership structure is a notable constraint. Telegraph Hill Partners controls roughly 70% of shares, leaving an extremely thin free float for a stock priced near $3.64. The most recent insider activity of substance was a coordinated CEO and CFO purchase in March at around $2.19 — both executives committed capital in size relative to the stock's liquidity, and the stock has since risen 66% from those levels. Options data provides little additional signal: the put/call ratio has been zero for most of the past three weeks, with only isolated put activity in mid-April, making options positioning essentially neutral into the print.
The May 8 call is now less about the Q1 numbers and more about whether management can articulate a credible path to narrowing the EBITDA loss — estimated at negative $7.3M for the full year — and what the demand environment looks like for its life sciences reagent business given the still-challenging biotech funding landscape.
See the live data behind this article on ORTEX.
Open TKNO on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
